Suppr超能文献

用于治疗住院特应性皮炎患儿的非标签用药。

Off-label medications in the treatment of hospitalized children with atopic dermatitis.

作者信息

Niedźwiedź Michał, Skibińska Małgorzata, Narbutt Joanna, Lesiak Aleksandra

机构信息

Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland.

出版信息

Postepy Dermatol Alergol. 2023 Feb;40(1):72-77. doi: 10.5114/ada.2022.119967. Epub 2022 Oct 10.

Abstract

INTRODUCTION

Off-label prescribing is defined as using medications outside conditions of the marketing authorisation including their licensed indications, dosage, age and route. Atopic dermatitis (AD) is the most common chronic skin condition in children which can be related to a high level of off-label prescribing.

AIM

To investigate the frequency of off-label prescribing and the medications involved in relation to indications and age in paediatric patients hospitalized for atopic dermatitis in a paediatric dermatology ward in 2019.

MATERIAL AND METHODS

One hundred and seventy-five consecutive discharge letters of patients were analysed regarding gender, age and medications used during hospital stay and prescribed on discharge. Each medication was checked against the licensed age and indications.

RESULTS

Altogether 564 medications were prescribed, including 289 topical and 275 systemic ones with 278 prescribed off-label (49.1%). Out of 289 topical medications, 113 (39.1%) were prescribed off-label regarding indications and 34 (11.76%) regarding the age of the patients. In the systemic medications group, 96 (34.53%) were prescribed off-label as AD was not a registered indication and 35 (12.73%) as the age of the patients was outside the marketing authorization. The most frequent medications prescribed off-label were antihistamines, antibiotics and corticosteroids.

CONCLUSIONS

Prescribing off-label in paediatric population is a common practice. Both topical and systemic medications are frequently used in AD patients off-label, therefore doctors should be familiar with the pitfalls of prescribing beyond the licensed indications and age.

摘要

引言

超说明书用药是指在药品上市许可规定的条件以外使用药物,包括其获批的适应证、剂量、适用年龄和给药途径。特应性皮炎(AD)是儿童中最常见的慢性皮肤病,这可能与较高水平的超说明书用药有关。

目的

调查2019年在一家儿科皮肤科病房因特应性皮炎住院的儿科患者中超说明书用药的频率以及与适应证和年龄相关的用药情况。

材料与方法

分析了175例连续出院患者的出院小结,内容涉及性别、年龄以及住院期间使用和出院时开具的药物。对照获批的年龄和适应证对每种药物进行检查。

结果

共开具了564种药物,其中包括289种外用药物和275种全身用药物,有278种属于超说明书用药(49.1%)。在289种外用药物中,113种(39.1%)在适应证方面属于超说明书用药,34种(11.76%)在患者年龄方面属于超说明书用药。在全身用药物组中,96种(34.53%)因AD不是注册适应证而属于超说明书用药,35种(12.73%)因患者年龄超出上市许可范围而属于超说明书用药。最常超说明书使用的药物是抗组胺药、抗生素和皮质类固醇。

结论

在儿科人群中超说明书用药是一种常见做法。外用和全身用药物在AD患者中都经常超说明书使用,因此医生应熟悉超出获批适应证和年龄用药的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/145b/9993195/4e607aec9147/PDIA-40-47932-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验